表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）的问世开启了 EGFR 突变非小细胞肺癌（NSCLC）的精准治疗时代，特别是三代 EGFR-TKI 奥希替尼，凭借着显著的全身和颅内疗效获益，已成为此类患者的一线标准治疗方案[1-3]。然而，EGFR-TKI 单药治疗存在一定的局限性，比如存在 EGFR L858R ...

临床试验资讯研究交流群（点击）在肺腺癌最为常见的EGFR突变患者中，EGFR基因19号外显子缺失突变从靶向药获益要强于L858R突变。为了增强L858R突变患者的靶向药获益，近日一项名为“FIRM”的中国临床研究给出了一个令人振奋的答案：将国产三代靶 ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells ...

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene ...

SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform ...

In a media release on Jan. 22, it was revealed that a group of scientists from the Agency for Science, Technology and ...

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R ...

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...

Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma Retrospective review of 33,850 molecularly profiled ...